Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 15/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.46 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6884460 | 0.86 | HSP90AB1 (0.55) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3855536 | 0.80 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3851009 | 0.80 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL29108620 | 0.80 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3855539 | 0.79 | HSP90AB1 (0.43) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL31058755 | 0.79 | HDAC6 (0.54) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL27854926 | 0.78 | CDK1 (0.71) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL13742935 | 0.78 | HDAC1 (0.43) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL8839971 | 0.77 | HDAC6 (0.46) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL6002747 | 0.77 | HSP90AB1 (0.42) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
| EP-1656387-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005012324-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | HSP90AB1 2759/4885HSP90AA1 3573/4885HDAC6 2419/4885 |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | HSP90AB1 2759/4885HSP90AA1 3573/4885HDAC6 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.